Lessons emerging from the evolving SERD landscape

Oral, next-generation SERDs are finally producing the clinical benefit needed to displace fulvestrant in hormone receptor-positive breast cancer after years of failures. The latest data mark a new chapter in the story of SERDs and showcase lessons about how to design clinical trials when standard of care is shifting and new mechanisms are coming into play.

The last two years have seen half a dozen milestones in oral selective estrogen receptor degrader (SERD) development, the capstone coming Thursday when AstraZeneca plc (LSE:AZN; NASDAQ:AZN) announced results from its oral SERD camizestrant, bringing the first step change in efficacy over fulvestrant, the sole marketed member of the class...